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The immune infiltrate within tumors has proved to be very powerful in the prognostic
stratification of patients and much attention is also being paid towards its predictive value.
In this work we therefore aimed at clarifying the significance and impact of PD-L1 and PD-
1 expression on the prognostic value of CD8+ tumor infiltrating lymphocytes (TILs) in a
cohort of consecutive patients with primary resected non-small cell lung cancer (NSCLC).
Tissue microarrays (TMA) were built using one representative formalin fixed paraffin
embedded block for every case, with 5 cores for each block. TMA sections were
stained with PD-L1 (clone SP263), PD-1 (clone NAT105) and CD8 (clone SP57).
Number of CD8+ cells per mm2 were automatically counted; median, 25th and 75th
percentiles of CD8+ cells were used as threshold for statistical clinical outcome analysis
and evaluated in patients subgroups defined by expression of PD-L1 and PD-1 within
tumors. We found an overall strong prognostic value of CD8+ cells in our cohort of 314
resected NSCLC, especially in PD-L1 negative tumors lacking PD-1+ TILs, and
demonstrated that in PD-L1 positive tumors a higher density of CD8+ lymphocytes is
necessary to improve the prognosis. Our data strengthen the concept of the importance
of the assessment and quantification of the immune contexture in cancer and, similarly to
what has been carried on in colorectal cancer, promote the efforts for the establishment of
an Immunoscore for NSCLC for prognostic and possibly predictive purposes.
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INTRODUCTION
Traditionally, tumor staging has always been performed
according to the evaluation of the pathological features defined
in the American Joint Committee on Cancer/Union for
International Cancer Control (AJCC/UICC) tumor-node-
metastasis (TNM) system (1).
However, the concurrent evaluation of the immune infiltrate
within tumors has proved to be very powerful in the stratification
of patients within different prognostic groups with higher
precision. As a matter of fact, the “Immunoscore” has reached
an advanced stage of development in colon cancer, where the
evaluation of the immune infiltrate, namely CD3+ and CD8+
lymphocytes, has been demonstrated to be an important
additional parameter to be integrated with the TNM (2). In
this regard, multicenter prospective studies have been
undertaken by an international task force with the aim to
further implement the use of the Immunoscore with the TNM
(designated TNM-I) in clinical practice (3). A similar effort has
been promoted for the evaluation of the role of tumor infiltrating
lymphocytes (TILs) in breast cancer (4). In non-small cell lung
cancer, different studies have evaluated the prognostic impact of
TILs using different approaches and methods in terms of types of
cells, compartment, scoring and material (5).
Along with the growing awareness of the importance of the
immune infiltrate as a variable for better prognostic
stratification, much attention is being paid towards its
predictive value. Immunotherapy targeting the PD-1/PD-L1
axis has shown remarkable efficacy in different tumor types
and has become the standard of care for the management of
locally advanced and metastatic NSCLC (6–9). Despite the great
promise held by PD-1/PD-L1 pathway inhibitors, in clinical
trials, only a fraction of unselected patients with advanced
NSCLC showed sustained response (6, 7). Thus, the selection
of patients with the highest chance of response is critical;
however, so far, only the evaluation of PD-L1 expression has
been approved for guiding treatment decisions for anti PD-1/
PD-L1 therapy (8, 9). Strategies for implementing the predictive
potential of PD-L1 testing are therefore urgently needed. In this
regard, a better understanding of the interaction between the
PD-1/PD-L1 axis and tumor-infiltrating lymphocytes is of
critical importance. In this work we therefore aimed at
clarifying such interaction by assessing the significance and
impact of PD-L1 and PD-1 expression on the prognostic value
of CD8+ TILs in NSCLC.
METHODS
Patients
The study cohort consisted of consecutive patients with primary
NSCLC who had undergone surgical resection at the IRCCS
Sacro Cuore Don Calabria Hospital of Negrar, Verona, Italy,
between 2003 and 2018 and for whom slides and paraffin-
embedded tissue blocks were available. None of the patients
received neoadjuvant chemotherapy or radiotherapy prior to
thoracic surgery. Tumors were classified according to the 2015
WHO classification, and staging was done by using the TNM
staging manual (eight edition) (1). Patient demographics and
clinical data were retrieved from the institution’s digital archives.
The investigations were conducted according to the principles
expressed in the Declaration of Helsinki
Tissue Samples and
Immunohistochemistry (IHC)
For each case, all hematoxylin and eosin–stained slides were
reviewed for confirmation of diagnosis; one block was then
selected for tissue microarrays (TMAs) construction. For each
block, five cores with a diameter of 1 mm were obtained from
diverse areas of the tumor and randomly numbered from 1 to 5.
From each TMA 5-mm sections were cut and stained with CD8
(clone SP57, Ventana Medical Systems, Tucson, AZ), PD-1
(clone NAT105, Roche, Basel, Switzerland) and PD-L1 (clone
SP263, Roche, Basel, Switzerland) on an automated staining
platform (Benchmark Ultra [Ventana Medical Systems]). An
OptiView DAB IHC Detection Kit (Ventana Medical Systems)
and an OptiView Amplification Kit (Ventana Medical Systems)
were used according to the manufacturer’s recommendations for
visualization of the primary anti-CD8, anti-PD-1 and anti–PD-
L1 antibodies. Stained sections were scanned with a Ventana iScan
HT slide scanner (Ventana Medical Systems). PD-L1 expression
was evaluated independently by two pathologists (GB and GR) and
calculated as the percentage of tumor cells with membrane staining
of any intensity for each core; the final score was calculated as the
average of all available cores. Cases were considered positive for PD-
L1 when ≥1% of the tumor cells expressed PD-L1. Discordant cases
were re-evaluated by both pathologist for consensus. PD-1 was
evaluated by two pathologists (EM and GQ) and scored as the
percentage of positive immune cells for each core, using the median
as cut-off value for each case. Concerning CD8, the absolute
numbers of CD8-positive cells per mm2 were automatically
counted using QuPath version 0.2.0 (10). The cut-off value for
CD8 expression was determined as the median absolute number.
Subsequently, the 25th and 75th percentiles absolute number were
used as threshold for statistical clinical outcome analysis.
Statistical Analysis
Data were imported and analyzed using STATA/IC for windows
version 14.0.
Chi-square tests were used to statistically analyze the
association between CD8 positive cells, clinicopathological
variables and PD-L1 and PD-1 expression.
Disease-free survival (DFS) was calculated from the date of
surgery to the date of recurrence or the date of death from any
cause. Overall survival (OS) was calculated from the date of
surgery to the date of death from any cause. For stage IV patients
OS only was considered. Patients alive and not relapsing or alive
regardless of relapsing were censored at the time of their last
follow-up visit for DFS and OS, respectively. Long-term survivors
were censored at 120 months of follow-up. Cumulative incidence of
DFS and OS in the groups was described by the Kaplan–Meier
method and compared with the log-rank test.
Munari et al. CD8+ TILs in NSCLC
Frontiers in Immunology | www.frontiersin.org May 2021 | Volume 12 | Article 6809732
The Cox proportional hazard regression model was used to
evaluate the associations between clinicopathological factors (sex,
age, histology, surgery, stage, therapy) and clinical outcome.
A two-sided P value <0.05 was considered statistically significant.
RESULTS
Clinico-Pathologic Features
Overall, 314 patients with tissue-confirmed resected NSCLC
were included in this study. The median age at diagnosis was
70 (range 40–86) years and 221 (70.4%) patients were men. The
most prevalent histology was adenocarcinoma (71.4%). The
majority of patients underwent lobectomy (77.1%) and had
stage I/II disease (76.1%). Adjuvant treatment, consisting of
chemotherapy and/or radiotherapy, was performed in 44
patients; none of the patients received immunotherapy. PD-L1
expression was seen in 106 of 314 NSCLC (33.8%). The mean and
median number of CD8-positive cells were 750 (SD: 635) and 575
(range: 10–3015) per mm2, respectively. The cut-off value for CD8
expression was determined as the median absolute number and
cases were considered positive when CD8-positive cells ≥575
per mm2 were observed. The clinicopathologic features based on
CD8 median expression are shown in Table 1, where it can be seen
a clear association between amount of CD8 lymphocytes and PD-L1
expression on tumors cells, as well as a positive correlation with PD-
1 expression (analysis possible for 297 cases). Indeed, PD-L1
expression in tumor cells and PD-1 expression in TILs showed a
positive correlation (Supplementary Table 1). The median number
of CD8 positive lymphocytes, in the PD-L1 negative and positive
tumors, was 505 and 813 per mm2 respectively. Considering this
different amount of CD8+ lymphocytes in the PD-L1 negative and
positive subgroups, the DFS and OS analysis was performed using
both the median (575 per mm2) and the first (300 per mm2) and
third (950 per mm2) quartiles as the threshold.
There were no other significant differences in patients’
characteristics between groups based upon CD8 median
expression except for gender.
Clinical Outcome
In the entire cohort, disease progression analysis could be
performed in 234 patients: in 63 patients follow-up was
unknown, while 16 were excluded because had distant
metastases at the time of diagnosis. Disease progression
TABLE 1 | CD8+ TILs in 314 NSCLC in relation to clinicopathologic variables.
Overall (%) CD8+ TILs P value
< 575 x mm² (%) ≥ 575 x mm² (%)
Patients 314 154 160
Sex
Male 221 (70.4) 100 (45.3) 121 (54.7) 0.03
Female 93 (29.6) 54 (58.1) 39 (41.9)
Age (years)
≤70 163 (51.9) 79 (48.5) 84 (51.5) 0.83
>70 151 (48.1) 75 (49.7) 76 (50.3)
Histology
Adenocarcinoma 224 (71.4) 107 (48.5) 84 (51.5) 0.73
SCC 72 (22.9) 37 (51.4) 35 (48.6)
Others 18 (5.7) 10 (55.6) 8 (44.4)
Surgery
Wedge/Segmentectomy 56 (17.8) 24 (42.8) 32 (57.2) 0.51
Lobectomy 244 (77.7) 122 (50) 122 (50)
Pneumonectomy 14 (4.5) 8 (57.1) 6 (42.9)
TNM Stage
I 159 (50.6) 77 (48.4) 82 (51.6) 0.30
II 80 (25.5) 45 (56.2) 35 (43.8)
III 53 (16.9) 26 (49.1) 27 (50.9)
IV 16 (5.1) 5 (31.3) 11 (68.7)
Unknow 6 (1.9) 1 5
Adjuvant Treatment
No 242 (77.1) 144 (47.1) 128 (52.9) 0.14
Yes 44 (14.0) 26 (59.1) 18 (40.9)
Unknow 28 (8.9) 14 14
PD-L1 (1% threshold)
Negative 208 (66.2) 122 (58.7) 86 (41.3) 0.00
Positive 106 (33.8) 32 (30.2) 74 (69.8)
PD-1 (7.5% threshold)
Negative 143 (45.6) 92 (59.7) 51 (31.9) 0.00
Positive 154 (49.0) 56 (36.4) 98 (61.2)
Unknow 17 (5.4) 6 (3.9) 11 (6.9)
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occurred in 90 patients: 33 experienced loco-regional recurrence
and 57 distant metastases. The median relapsing time was 12
months (95% C.I. 10-16). Overall survival analysis was possible
in 293 patients: 120 patients were dead at the time of analysis.
The median time to death was 27 months (95% C.I. 23-30).
Patients alive and disease-free at the time of analysis had a
median follow-up of 50 months (95% C.I. 41-56).
Survival Analysis According to CD8+ TILs Density
The group of patients whose tumors showed high CD8+ cell
density (≥575 per mm2) showed a significant increase in DFS
(median 34.5 months; 95% C.I. 26-47) compared to the group with
lowCD8+ cell density (<575 permm2) (medianDFS: 25months; 95%
C.I. 20-29; p=0.000) (Figure 1A). OS was also significantly increased
in high CD8+ cell density group (median 41 months; 95% C.I. 37-49)
as compared with the low CD8+ cell density group (median 32.5
months; 95% C.I. 28-37; p=0.014) (Figure 1B).
Multivariate Cox proportional hazards regression analysis
showed that both high density of CD8+ cells and stage I were
favorable prognostic factor for DFS and OS while female sex was
associated with significantly better OS (Table 2A).
Higher CD8 TILs density was associated with better DFS also
using both 25th (300 per mm2) and 75th (950 per mm2) percentile





FIGURE 1 | Kaplan-Meier curves for DFS and OS based on CD8+ TILs using the median as the threshold in all (A, B), in PD-L1 negative (C, D) and PD-L1 positive
(E, F) NSCLC.
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Survival Analysis According to PD-L1
and PD-1 Expression
PD-L1 expression was associated neither with DFS (p=0.862) nor
with OS (p=0.882), even after subgroup analysis according to low
CD8+ TILs density (DFS: p=0.741; OS: p=0.853) or high CD8+
TILs density (DFS: p=0.346; OS: p=0.467).
PD-1 expression was associated with neither DFS (p=0.114)
nor OS (p=0.142) when considering the entire cohort.
Survival Analysis According to CD8+ TILs Density
Using the Median (575 CD8+ Cells per mm2) as the
Threshold and PD-L1 and PD-1 Expression
When patients with PD-L1 negative tumors were considered,
high density of CD8+ cells was associated with a significantly
better DFS (median 37 months; 95% C.I. 26-50) and OS
(median 45 months; 95% C.I. 37-52) compared to those with
low CD8+ cells density (median DFS: 25.5 months, 95% C.I. 20-
30, p=0.003; median OS: 34 months, 95% C.I. 30-39, p=0.017)
(Figures 1C , D). The positive prognostic value of high CD8+
cell density was also maintained in multivariate analysis
(Table 2B). Better DFS and OS was demonstrated also for
patients with tumors with high CD8+ cells density lacking PD-1
expression, but not for cases with PD-1+ TILs (Supplementary
Figures 2A, B). An even bigger difference in both DFS
(p=0.000) and OS (0.003) emerged for patients with PD-L1
negative tumors with high density of CD8+ TILs lacking PD-1
expression (Supplementary Figure 3).
Conversely, there were not significant differences in DFS and
OS within the of PD-L1 positive tumors subgroup
(Figures 1E, F).
Survival Analysis According to PD-L1 Expression
and CD8+ TILs Density Using the 25th Percentile (300
CD8+ Cells per mm2) as the Threshold
In this setting the results are superimposable to those observed
previously, where the CD8 median was used as threshold. Within
the PD-L1 negative tumors subgroup, patients with tumors with
high CD8+ cell density showed significantly better DFS (median
32 months; 95% C.I. 26-39) and OS (median 40.5 months; 95%
C.I. 33-46) compared to those with low CD8+ cell density
(median DFS: 20 months, 95% C.I. 17-30, p=0.000; median
OS: 35 months, 95% C.I. 23-41, p=0.004) (Figures 2A, B). The
positive prognostic value of CD8 expression was also maintained
in multivariate analysis (Table 3A). Conversely, there were not
significant differences in terms of DFS and OS when PD-L1
positive tumors were considered (Figures 2C, D).
Survival Analysis According to PD-L1 Expression
and CD8+ TILs Density Using the 75th Percentile
(950 CD8+ Cells per mm2) as the Threshold
Here the results are opposite to the two previous settings. When
patients with PD-L1 negative tumors were considered, there were
no significant differences in terms DFS and OS with respect to
CD8+ TILs density (Figures 3A, B). On the other hand, PD-L1
positive tumors with high CD8+ TILs density were associated
with a significantly longer DFS (median 52.5 months; 95% C.I.
27-70) compared with low CD8+ TILs density (median 20
months; 95% C.I. 17-30; p=0.002). Regarding OS, there was
also a trend towards a statistically significant difference between
high CD8+ TILs density (median 52.5 months; 95% C.I. 39-73)
and low CD8+ TILs density (median 27 months; 95% C.I. 23-36;
p=0.058) (Figures 3C, D). The positive prognostic value of high
CD8+ cell TILs density was also maintained in multivariate
analysis (Table 3B).
TABLE 2 | Multivariate analysis of predictors of DFS and OS in all NSCLC (A)
and in PD-L1 negative NSCLC (B) using the median of CD8+ TILs as the
threshold.
Variables DFS OS




Female 0.73 0.47-1.12 0.15 0.62 0.39-1.00 0.05
Age (years)
≤70 1 1
>70 0.94 0.62-1.42 0.78 1.08 0.69-1.07 0.71
Histology
Adenocarcinoma 1 1
Others 0.86 0.56-1.31 0.49 0.86 0.55-1.34 0.51
Surgery
Wedge/Lobectomy 1 1
Pneumonectomy 0.57 0.25-1.27 0.17 0.76 0.34-1.69 0.50
AdJuvant Treatment
No 1 1
Yes 1.00 0.58-1.73 0.97 1.14 0.64-2.01 0.65
TNM Stage
II - IV 1 1
I 0.27 0.17-0.43 0.00 0.31 0.19-0.50 0.00
CD8
<575/mm² 1 1




Female 0.64 0.39-1.06 0.08 0.57 0.33-099 0.04
Age (years)
≤70 1 1
>70 1.07 0.65-1.76 0.76 1.24 0.73-2.11 0.42
Histology
Adenocarcinoma 1 1
Others 0.85 0.48-1.50 0.59 0.67 0.36-1.24 0.21
Surgery
Wedge/Lobectomy 1 1
Pneumonectomy 0.36 0.10-1.23 0.10 0.63 0.18-2.14 0.46
AdJuvant Treatment
No 1 1
Yes 1.01 0.51-1.96 0.97 1.08 0.53-2.18 0.82
TNM Stage
II - IV 1 1
I 0.25 0.14-0.44 0.00 0.30 0.17-0.53 0.00
CD8
<575/mm² 1 1
≥575/mm² 0.43 0.25-0.73 0.00 0.49 0.28-0.83 0.00
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DISCUSSION
Our study confirms the overall strong prognostic value of CD8+
TILs in NSCLC using a digital approach for automatic absolute
quantification of CD8+ cell density and provide evidence that in
PD-L1 positive tumors, a higher density of CD8+ lymphocytes is
necessary to improve the prognosis. In other words, if tumors do
not express PD-L1, even few CD8+ cells can exert their antitumor
effect; on the contrary, if tumors do express PD-L1, a higher
number of CD8+ TILs is required in order to improve survival.
Moreover, the presence of an efficient population of cytotoxic
cells with low PD-1 expression is associated with prolonged DFS
and OS, especially within tumors lacking PD-L1.
Traditional tumor staging schemes are based on the TNM
classification in order to evaluate the extent of cancer spread,
estimate patient outcome and guide therapeutic approaches for a
variety of tumor types (1). However, significant differences exist
between patients within the same pathological stages, underlying
the limitations of the TNM system. Different parameters have
been thus taking into consideration to refine cancer
classification, including tumor immunophenotype, molecular
and genetic features, often underestimating the important role
of tumor microenvironment.
The last years have witnessed a paradigm shift from a tumor-
centric view, mostly focused at detecting tumor cell features
through the extensive use of “omics” approaches, to a more
comprehensive consideration of the tumor microenvironment
(TME) and immune components. Indeed, understanding the
critical role of the antitumor activity of both innate and adaptive
immune system for patient’s survival and the development of the
concept of “immune contexture” represent important advances
in oncology (11). As a matter of fact, in recent years, many efforts
have been made in order to assess the prognostic impact of
multiple immune cell types within the microenvironment of
different tumors. Among the most important achievements in
this field of investigation is the immunoscore, an assay based on
the digital quantification of CD3+ and CD8+ lymphocytes both at
the edge and at the center of tumors, which provides a scoring
system defined as low or high in both locations. Such
combination proved to be more precise than the TNM in
predicting disease free survival, disease specific survival ad
overall survival in stage I, II and III colorectal cancer (3, 12).
In general, besides the combination of CD3+ ad CD8+
lymphocytes, it appears that the TILs subtype with the
strongest positive prognostic impact is represented by CD8+
cytotoxic T cells, as demonstrated across several cancer types (11,
13). Also in lung cancer different studies have assessed the
prognostic impact of TILs with different methodologies with
regards to type of cell evaluated, compartment (stroma and/or
intraepithelial cells), scoring (continuous vs semiquantitative),
quantification (manual vs digital) and type of material (tissue
microarrays vs whole sections); overall it appears that CD8+ cells
A B
DC
FIGURE 2 | Kaplan-Meier curves for DFS and OS based on CD8+ TILs using the 25th percentile as the threshold in PD-L1 negative (A, B) and PD-L1 positive (C, D) NSCLC.
Munari et al. CD8+ TILs in NSCLC
Frontiers in Immunology | www.frontiersin.org May 2021 | Volume 12 | Article 6809736
are the most promising, regardless of the compartment analyzed,
with some variation in the statistical trends (5). Although studies
have demonstrated high concordance between manual and
digital quantification (14), digital imaging may improve
reproducibility in the assessment of TILs compared with visual
semiquantitative methods, and is advocated by the authors of the
immunoscore (2). We have therefore chosen a digital approach
for automatic absolute quantification of CD8+ cell density, using
tissue microarrays. PD-L1 was instead evaluated visually as
recommended by guidelines while PD-1 was defined as the
percentage of positive TILs. Considering the median of CD8+
cell density as the threshold, we found a significant improvement
in terms of DFS and OS for patients with tumors with high CD8+
cells density compared with low CD8+ cells density and such
difference proved to be significant in multivariate analysis. This
result is in line with what reported by Donnem et al. (15). These
authors evaluated stromal CD8+ lymphocytes in a total of 797
NSCLC using a three-tiered approach based on manual
evaluation of the percentage of CD8+ cells over total amount
of nucleated cells. These authors found that stromal CD8+ TILs
TABLE 3 | Multivariate analysis of predictors of DFS and OS in PD-L1 negative NSCLC using the 25th percentile of CD8+ TILs (A) and in PD-L1 positive NSCLC using
the 75th percentile of CD8+ TILs as threshold (B).
Variables DFS OS




Female 0.62 0.38-1.02 0.06 0.57 0.33-0.98 0.04
Age (years)
≤70 1 1
>70 1.20 0.74-1.97 0.45 1.25 0.74-2.12 0.40
Histology
Adenocarcinoma 1 1
Others 0.95 0.55-1.66 0.87 0.70 0.38-1.28 0.24
Surgery
Wedge/Lobectomy 1 1
Pneumonectomy 0.36 0.11-1.20 0.09 0.64 0.19-2.16 0.48
AdJuvant Treatment
No 1 1
Yes 1.04 0.54-1.20 0.91 1.12 0.56-2.23 0.74
TNM Stage
II - IV 1 1
I 0.28 0.16-0.49 0.00 0.31 0.17-0.55 0.00
CD8
<300/mm² 1 1




Female 0.91 0.38-2.21 0.84 0.66 0.24-1.83 0.43
Age (years)
≤70 1 1
>70 0.54 0.22-1.30 0.17 0.81 0.33-2.03 0.66
Histology
Adenocarcinoma 1 1
Others 1.01 0.51-2.00 0.51 1.25 0.62-2.54 0.52
Surgery
Wedge/Lobectomy 1 1
Pneumonectomy 1.02 0.34-3.10 0.96 0.96 0.32-2.92 0.95
AdJuvant Treatment
No 1 1
Yes 0.60 0.19-1.87 0.19 0.95 0.30-2.91 0.92
TNM Stage
II - IV 1 1
I 0.28 0.11-0.72 0.00 0.32 0.12-0.82 0.02
CD8
<950/mm² 1 1
≥950/mm² 0.28 0.12-0.65 0.00 0.47 0.21-1.03 0.06
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density has independent prognostic value in resected NSCLC in
all endpoints (DFS, DSS and OS). At variance with this study, we
used an absolute count of CD8+ cells per mm2 using an open-
source software (10). Such method, in our opinion, eliminates
interobserver variability and has the advantage of being quicker
and more reproducible. We wanted to use the simplest method
to define the threshold and decided to use the median of CD8+
cells as the cutoff, which resulted to be 575 cells per mm2. The
same approach has been used by Kim et al. (16), who evaluated
both CD8+ cells and PD-L1 expression in a smaller cohort of
resected NSCLC patients. These authors found that the
combination of high density of CD8+ cells and negative
expression of PD-L1 was associated with a much better
prognosis compared to all other CD8/PD-L1 combinations in
terms of both OS and relapse free survival (RFS). We validated
such observations on a larger cohort of patients and
demonstrated that the prognostic significance of CD8+ cells is
significantly influenced by PD-L1 expression in NSCLC. Indeed,
when patients with PD-L1-negative tumors were considered, a
significant independent prognostic impact of CD8+ TILs was
observed using the first quartile and the median as the
thresholds. Better DFS and OS was demonstrated also for
patients with tumors with high CD8+ cells density lacking PD-1
expression, but not for cases with PD-1+ TILs. Moreover, an even
bigger difference in both DFS and OS emerged for patients with
PD-L1 negative tumors with high density of CD8+ TILs lacking
PD-1 expression. On the contrary, for patients with PD-L1-
positive tumors, CD8+ TILs were prognostically significant when
the third quartile was considered as the cutoff. A logical
explanation is that the presence of PD-L1 on tumor cells may
contribute to tumor immune evasion by inhibiting cytotoxic
lymphocytes, and only when they are in high number, they can
exert their antitumor effect. On the other hand, both CD4+ and
CD8+ lymphocytes, as well as NK cells, are known to induce PD-
L1 expression on tumor cells through an IFN-g mediated
mechanism (17, 18); therefore, it might be possible that an
immune-rich TME could in turn induce PD-L1 expression. In
this setting, it is reasonable to believe that a tumor expressing
PD-L1 and with a dense infiltrate of CD8+ TILs may respond
better to PD1/PD-L1 inhibitors. However, evaluation of PD-L1
expression on tumor cells is currently the only biomarker
approved to select patients for treatment with PD1/PD-L1 axis
inhibitors, with several limitations due to tumor heterogeneity
(19), differences between clones (20) and types of material (21).
Thus, PD-L1 positivity by itself does not appear to be sufficiently
accurate at present and therefore additional biomarkers for
better prediction of clinical response to anti PD-1/PD-L1
antibodies are urgently needed. In this regard, Fumet et al.
demonstrated that high expression of CD8+ in TILs evaluated
with both immunohistochemistry and mRNA quantification was
A B
DC
FIGURE 3 | Kaplan-Meier curves for DFS and OS based on CD8+ TILs using the 75th percentile as the threshold in PD-L1 negative (A, B) and PD-L1 positive (C, D) NSCLC.
Munari et al. CD8+ TILs in NSCLC
Frontiers in Immunology | www.frontiersin.org May 2021 | Volume 12 | Article 6809738
significantly associated with response rate and progression free
survival in a cohort of 85 patients treated with nivolumab in
second or third line. Importantly, these authors reported that
high mRNA expression of both CD8 and PD-L1 outperformed
the discriminatory properties of CD8 or PD-L1 alone, both at
immunohistochemical and mRNA expression level (22). In
another paper, Mazzaschi et al. demonstrated that resected
NSCLC tumors highly infiltrated by CD8+ TILs with low PD-1
expression showed improved progression free survival in
patients treated with nivolumab (23). Overall, it appears that
understanding the immune contexture within tumors would not
only improve the prognostic stratification of patients but could
effectively play a major role in treatment decision, refining
prediction of response to PD-1/PD-L1 axis inhibitors and
future immunomodulatory agents. It is conceivable that in the
foreseeable future, parameters relative to the immune contexture
will gain more and more importance across different cancer types
and will be included into the TNM staging system. The
immunoscore developed for colon cancer proved to be an
important example of a simple yet effective approach for the
assessment of the immune microenvironment of tumors that is
now approved for clinical use as an in vitro diagnostic test for
colorectal cancer (24, 25).
In conclusion, in this study we added further data to support
the notion that CD8+ TILs represent an efficient tool to refine
prognostic stratification in NSCLC, for which we advocate the
use of digital counting as a reproducible and less time-
consuming method for quantification. Moreover, we
demonstrated that PD-L1 expression has an impact on the
prognostic value of CD8+ cells density, since its presence on
tumor cells requires a higher density of CD8+ lymphocytes in
order for them to exert antitumor function and therefore
enhance patient survival. An even stronger prognostic impact
for CD8+ cells was demonstrated in PD-L1 negative tumors
lacking PD-1+ TILs. Our data strengthen the concept of the
importance of the assessment and quantification of the immune
contexture in cancer and, similarly to what has been carried on in
colorectal cancer, promote the establishment of an immunoscore
for NSCLC. Such immunoscore should take into consideration a
dynamic threshold for CD8+ TILs based on the expression of
PD-L1 in neoplastic cells and PD-1 on immune cells. Such
approach may be applied to different tumors, including
pediatric ones such as metastatic neuroblastoma, known to
express PD-L1 (26), for which the current therapies are largely
unsuccessful. Given the important interaction between the PD-1/
PD-L1 immune axis and CD8+ cell function, further studies
aiming at better defining the predictive role of TILs for
immunotherapy are needed.
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